Press Releases

The following are official statements issued by UsAgainstAlzheimer’s in response to major national policy actions, industry events, breaking news, or organizational achievements. Please see the UsAgainstAlzheimer’s press kit page for additional information. For media requests, please contact Cassie Scher at or 479-387-4113.

  • September 10, 2021

    UsAgainstAlzheimer’s Applauds Inclusion of Paid Leave Policy in New Budget Reconciliation Legislation

    The bill’s provision of twelve weeks of paid leave would help millions...

    Read more
  • August 24, 2021

    New Survey Finds 9 in 10 in Alzheimer’s and Dementia Community See Importance of Early Detection

    new survey of the UsAgainstAlzheimer’s A-LIST® shows nearly 90 percent of...

    Read more
  • July 29, 2021

    UsAgainstAlzheimer’s Praises Progress in Alzheimer’s Funding in House Appropriations Bill

    UsAgainstAlzheimer’s (UsA2) praised the progress made in the Alzheimer’s disease and related spending provisions...

    Read more
  • July 20, 2021

    UsAgainstAlzheimer’s Center for Brain Health Equity Spotlights the 41 Congressional Districts with the Highest Prevalence of Alzheimer’s among Blacks and Latinos

    UsAgainstAlzheimer’s Center for Brain Health Equity released a new data brief today...

    Read more
  • July 19, 2021

    UsAgainstAlzheimer’s Praises Proposed New National Risk Reduction Goal for Alzheimer’s and Related Dementias

    UsAgainstAlzheimer’s today praised the decision by the National Alzheimer’s Project Act (NAPA)...

    Read more
  • June 24, 2021

    UsAgainstAlzheimer’s Applauds Progress with New Lilly and Eisai/Biogen Drug Treatments That Offer the Promise of More Choices to Alzheimer’s Patients

    UsAgainstAlzheimer’s today issued the following statement from George Vradenburg, chairman and co-founder...

    Read more
  • June 21, 2021

    New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

    The FDA’s approval of Aduhelm is a breakthrough in the fight to...

    Read more
  • June 07, 2021

    UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

    "This first disease-slowing drug is a dramatic turning point in the fight...

    Read more
  • May 19, 2021

    UsAgainstAlzheimer’s Welcomes Bipartisan Introduction of CHANGE Act to Encourage Early Detection and Diagnosis of Alzheimer’s

    UsAgainstAlzheimer’s welcomed the bipartisan introduction today in Congress of the CHANGE Act...

    Read more

Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer's. This report found that deep social inequities exist in countries highly impacted by Alzheimer's among Latinos and Blacks.